RE:Four months todayThe PGX scale up for the go it alone Y-BG immune booster was to add about $100M to its NPV based on the Y-BG portion of the immune booster market and what CEAPRO could conservatively capture. It won't be a straight line move but as the scale up progresses to commercial production, that works out to an additional $100M ($1.25/share) to the current market cap.